Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To describe the immunogenicity of bivalent rLP2086 as determined by hSBA titers to primary test strains at approximately 6, 12, 18, 24, 36, and 48 months after the last dose (second or third dose) of bivalent rLP2086 in the primary study (ie, a previously conducted Pfizer study using the final formulation and dose of bivalent rLP2086).
Critère d'inclusion
- Meningococcal type B Bacterial Meningitis